RT Journal Article
SR Electronic
T1 Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.10.21264827
DO 10.1101/2021.10.10.21264827
A1 Robert L. Atmar
A1 Kirsten E. Lyke
A1 Meagan E. Deming
A1 Lisa A. Jackson
A1 Angela R. Branche
A1 Hana M. El Sahly
A1 Christina A. Rostad
A1 Judith M. Martin
A1 Christine Johnston
A1 Richard E. Rupp
A1 Mark J. Mulligan
A1 Rebecca C. Brady
A1 Robert W. Frenck, Jr.
A1 Martín Bäcker
A1 Angelica C. Kottkamp
A1 Tara M. Babu
A1 Kumaravel Rajakumar
A1 Srilatha Edupuganti
A1 Ann R. Falsey
A1 Christine M. Posavad
A1 Janet I. Archer
A1 Sonja Crandon
A1 Seema U. Nayak
A1 Daniel Szydlo
A1 Jillian Zemanek
A1 Clara P. Dominguez Islas
A1 Elizabeth R. Brown
A1 Mehul S. Suthar
A1 M. Juliana McElrath
A1 Adrian B. McDermott
A1 Sarah E. O’Connell
A1 David C. Montefiori
A1 Amanda Eaton
A1 Kathleen M. Neuzil
A1 David S. Stephens
A1 Paul C. Roberts
A1 John H. Beigel
A1 the DMID 21-0012 Study Group
YR 2021
UL http://medrxiv.org/content/early/2021/10/13/2021.10.10.21264827.abstract
AB Background While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen.Methods In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-μg, Janssen Ad26.COV2.S 5×1010 virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations). The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29.Results 458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 154 received BNT162b2 booster vaccines. Reactogenicity was similar to that reported for the primary series. Injection site pain, malaise, headache, and myalgia occurred in more than half the participants. Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2-76-fold) and binding antibody titers (4.6-56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2-20-fold whereas heterologous boost increased titers 6.2-76-fold. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations.Conclusion Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier.(Funded by National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04889209)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04889209Funding StatementThe trial was sponsored and primarily funded by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), under award numbers UM1AI48372, UM1AI148373, UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148574, UM1AI148575, UM1AI148576, UM1AI148684, UM1 AI148689 and with support from the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00050 and NIH Vaccine Research Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra Center for IRB IntelligenceI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data produced in the present work are contained in the manuscript